Do you have preferred regimens for young patients (<30 y/o) with early stage DLBCL?

Guidelines indicate RCHOPx3 +RT as category I and RCHOP x 6 below that; long term f/u for SWOG 8736 showed similar PFS and OS. Do you have and approaches to decide on toxicity vs benefit of different options in younger patients?

Answer from: Radiation Oncologist at Academic Institution

For patients with early-stage, non-bulky disease, 3 cycles of R-CHOP + ISRT (30 Gy) provides excellent outcomes. This strategy is particularly attractive if the site(s) of disease requiring irradiation would engender a very low risk of late effects from RT (e.g., an inguinal lymph node). In the rand...

Comments

Medical Oncologist at The Christ Hospital Network
I agree with RT benefits but would be very concern...

Please select the option that best describes you:

Do you have preferred regimens for young patients (<30 y/o) with early stage DLBCL?

Related Questions